Next Article in Journal
Genus Nocardiopsis: A Prolific Producer of Natural Products
Next Article in Special Issue
S-Assimilation Influences in Carrageenan Biosynthesis Genes during Ethylene-Induced Carposporogenesis in Red Seaweed Grateloupia imbricata
Previous Article in Journal
Characteristics of Marine Biomaterials and Their Applications in Biomedicine
Previous Article in Special Issue
Antimicrobial Diterpene Alkaloids from an Agelas citrina Sponge Collected in the Yucatán Peninsula
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 20
Issue 6
10.3390/md20060373
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Development of the Bengamides as New Antibiotics against Drug-Resistant Bacteria

by
Cristina Porras-Alcalá
1,
Federico Moya-Utrera
1,
Miguel García-Castro
1,
Antonio Sánchez-Ruiz
2,
Juan Manuel López-Romero
1,
María Soledad Pino-González
1,
Amelia Díaz-Morilla
1,
Seiya Kitamura
3,4,
Dennis W. Wolan
3,
José Prados
5,6,7,
Consolación Melguizo
5,6,7,
Iván Cheng-Sánchez
8,* and
Francisco Sarabia
1,*
1
Department of Organic Chemistry, Faculty of Sciences, University of Malaga, 29071 Málaga, Spain
2
Faculty of Pharmacy, Campus de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain
3
Department of Molecular Medicine, The Scripps Research Institute, San Diego, CA 92037, USA
4
Department of Biochemistry, Albert Einstein College of Medicine, New York, NY 10641, USA
5
Center of Biomedical Research (CIBM), Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100 Granada, Spain
6
Department of Anatomy and Embriology, Faculty of Medicine, University of Granada, 18071 Granada, Spain
7
Instituto de Investigación Biosanitaria ibs, Granada, 18012 Granada, Spain
8
Department of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
*
Authors to whom correspondence should be addressed.
Mar. Drugs 2022, 20(6), 373; https://doi.org/10.3390/md20060373
Submission received: 27 April 2022 / Revised: 24 May 2022 / Accepted: 25 May 2022 / Published: 31 May 2022
(This article belongs to the Special Issue Marine Drugs Research in Spain)
Browse Figures
Review Reports Versions Notes

Abstract

:
The bengamides comprise an interesting family of natural products isolated from sponges belonging to the prolific Jaspidae family. Their outstanding antitumor properties, coupled with their unique mechanism of action and unprecedented molecular structures, have prompted an intense research activity directed towards their total syntheses, analogue design, and biological evaluations for their development as new anticancer agents. Together with these biological studies in cancer research, in recent years, the bengamides have been identified as potential antibiotics by their impressive biological activities against various drug-resistant bacteria such as Mycobacterium tuberculosis and Staphylococcus aureus. This review reports on the new advances in the chemistry and biology of the bengamides during the last years, paying special attention to their development as promising new antibiotics. Thus, the evolution of the bengamides from their initial exploration as antitumor agents up to their current status as antibiotics is described in detail, highlighting the manifold value of these marine natural products as valid hits in medicinal chemistry.

1. Introduction

The bengamide family of natural products (1–24) constitutes a group of interesting and inspiring molecules that has elicited intense research directed toward their total synthesis, analogue design, and biological and medicinal studies due to their potent antitumor properties [1]. The isolation of the first members of bengamides, A (1) and B (2) was in 1986 by Crews/Quiñoá et al. [2] from an undescribed specimen of a sponge belonging to the Jaspidae family in Benga Lagoon (Fiji Islands). This finding was followed by the discoveries of other members (bengamides C-Q) from other sponges, including Jaspis cf. coriacea [3,4], Jaspis digonoxea [5], Jaspis carteri [6], Jaspis splendens [7], Pachastrissa sp. [8], Dorypleres splendens [9], Stelleta sp. [10] and Calthropella sp. [11]. Interestingly, the discoveries by Crews [12] and later by Brönstrup et al. [13] of the bengamides E (5), F (6), E’ (7), and F’ (8) from the terrestrial myxobacteria Myxococcus virescens strengthened the initial hypothesis that the bengamides were the result of a symbiotic interaction between the sponges and bacteria [14], a notion that was proposed in virtue of the presence of the end-chain isopropyl group, which is characteristic in bacterial fatty acids [15]. More recently, one new member of the bengamides, bengamide R (19), was isolated and characterized from Jaspis splendens sponges, collected in Mauritius, within a research programme directed towards the discovery and identification of new antimycobacterial agents from marine sources [16] (Table 1).
Structurally, the bengamides contain a unique molecular structure featured by a C-10 side chain possessing four contiguous hydroxyl groups and a terminal disubstituted E-olefin, linked to an aminocaprolactam moiety through an amide group, which is the main structural component that distinguishes the different members of these natural products [17]. In fact, according to the caprolactam ring, the bengamides are classified into two structural classes, which are the following: (a) Type I, which includes bengamides A-D, G–J, L–O, Y and Z, and that contains a hydroxylysine-derived caprolactam, bearing or not a lipidic chain; and (b) Type II that includes bengamides E, F, E’, F’ and P–S, that contains lysine-derived caprolactam. The cases of bengamide K (23) and isobengamide E (24) fall outside of this classification with the lack of the entire polyketide fragment possessing an N-formyl group instead of in 23, and with a different link between the polyketide and the caprolactam fragments in the isomeric 24 (Figure 1).
Preliminary biological evaluations of the bengamides revealed their prominent antitumor properties, displaying cytotoxicities in the 1.0 nM–3.3 μM range for the IC50 values against human breast MDA-MB-435 carcinoma cells, producing the arrest of the cells at both the G0/G1 and G2/M interfaces of the cell cycle and, as a consequence, apoptosis of tumoral cells [18]. The mode of action was disclosed by means of proteomic studies [19], revealing that the bengamides inhibited methionine aminopeptidases types 1 and 2 (MetAP1 and MetAP2), which was further demonstrated by the isolation of the complex enzyme-bengamide and its subsequent X-ray analysis [19]. This analysis allowed for the determination of the mode of interaction of the bengamides at the active site of these important enzymes, with the following key interactions: (1) a critical dinuclear metal centre placed as a deep invagination in the surface of the enzyme is coordinated with the hydroxyl groups at C3, C4, and C5; (2) interaction of the terminal isopropyl group of the olefin at the hydrophobic pocket P1, which contains the residues Phe-219, His-382 and Ala-414; and (3) the allocation of the caprolactam ring at the hydrophilic pocket P2, located at the solvent-exposed surface (Figure 2). As a consequence of the inhibition of methionine aminopeptidases by the bengamides, the activity of the proto-oncogene c-Src, involved in the development, growth, progression, and metastasis of numerous human cancers, is remarkably decreased, producing a delay in cell-cycle progression [20]. Therefore, it was possible to establish a link between cancer and inhibition of the MetAPs through the proto-oncogene c-Src and likely other oncogenes, which represent substrates for both MetAP1 and MetAP2, and, in this way, to justify the antitumoral effect of the bengamides. Interestingly, the enzyme MetAP2 is the biological target of the very well-known antiangiogenic compounds fumagillin and ovalicin [21,22], and their selectivities against MetAP2 is a key factor that is being explored, not only for the treatment of cancer but also for the development of antiobesity agents [23]. Thus, the toxicity found in the bengamides is attributable to the lack of selectivity against both MetAPs [24,25], and a future direction in this research might be the design of MetAP2-selective bengamides [26].
Given the outstanding antitumor properties displayed by the bengamides, an intense research activity has been devoted in relation to the bengamides directed towards the analysis, characterization, and development of bengamide-based anticancer candidates with antiangiogenic properties through the design, synthesis, and biological evaluation of analogues. In fact, one of the most active analogues identified was the compound LAF-389 (see Figure 3) [27,28], which reached a phase I clinical trials, which began in 2000. However, finally, this clinical trial was discontinued, and the bengamide analogue was withdrawn for further clinical investigations due to unanticipated cardiotoxicity [29]. In particular, from a total of 33 patients treated with LAF-389, eight patients suffered severe cardiovascular toxicity, which was not predicted during the preclinical studies in rats and dogs. As mentioned above, the first biological evaluations of the bengamides confirmed that these compounds possessed a broad array of biological activities, including not only antitumor activities, but also antihelmintic and antibiotic activities. In fact, bengamides A (1) and B (2) showed to be active against Streptococcus pyrogenes with MIC (Minimum inhibitory concentration that prevents visible growth of the bacteria) values of 4 and 2 μg/mL. However, their antibiotic properties were not further explored. As we will discuss in the present review, the ability of the bengamides to inhibit methionine aminopeptidases was recently exploited for the case of the MetAP of the Mycobacterium tuberculosis. Thus, it was found that bengamide A (1) was able to block the bacteria growth of this serious pathogenic agent. Therefore, this relevant finding broadens the therapeutic applications of the bengamides as new antibiotics with a novel mechanism of action. These stunning biological discoveries elicited the emerging interest for the bengamides as new potential antibiotics, and as a result, some bengamide analogues have been developed and proved to possess impressive antibiotic activities against various drug-resistant bacteria such as Mycobacterium tuberculosis and Staphylococcus aureus, expanding the biological applications of these enticing molecules.
The interest of our research group in the design and development of new antitumor agents based on bioactive natural products, led us to consider the bengamides as prime targets, starting a research programme directed to the establishment of an efficient, stereoselective and convergent synthesis that enabled the access to the natural bengamides [30,31,32] and analogs thereof for biological evaluations [33,34,35].
Therefore, due to the recent demonstration of the potential of the bengamides as a new class of antibiotics, we wish to report the advances achieved in this field, including the last progress in the chemistry and biology of these fascinating molecules since 2014, when we reported an extensive review about the bengamides and bengazoles.
The present review reports all these new discoveries, describing in detail the evolution of the bengamides from their initial exploration as antitumor agents up to their current status as antibiotics, highlighting the manifold value of these marine natural products as valid hits in medicinal chemistry.

2. Recent Progress in the Chemistry and Biology of the Bengamides

2.1. New Progress in Antitumor Properties of the Bengamides

After the publication of our review about the chemistry and biology of the bengamides and bengazoles in 2014 [1], a new review was published in 2017 by Crews et al. [36]. In summary, until 2014, a total of 111 analogues of the bengamides were synthesized [27,37,38,39,40,41], together with numerous total syntheses of the natural congeners [42,43,44,45,46], by different research groups, and biologically evaluated against different tumor cell lines, which, overall, represents an extensive and thorough structure-activity relationship study that has allowed for the establishment of a consistent and well-defined pharmacophore for the bengamides, summarized in the following points: (a) the importance of the substituent at the terminal olefinic position; (b) the essential role of the polyketide fragment, whose hydroxyl groups and stereochemistries are essential for their biological properties; and; (c) the beneficial impact of the modification of the caprolactam fragment in their antitumor properties. Among the analogues that displayed improved pharmacological properties in comparison with the natural counterparts, were the bengamide A analogue 25, known as LAF389, which presented a greater solubility in water with respect to bengamide A (1), or the modified caprolactam analogue 26, the cyclopentyl analogue of bengamide E 27, or the ring-opened bengamide analogue 28, which exhibited a major antitumor potency compared with bengamide E (5), being analogue 28 the most potent analogue identified so far (Figure 3).
In 2015, Brönstrup and coworkers isolated bengamides E (5), F (6), E’ (7) and F’ (8) from the terrestrial myxobacterium Myxococcus virescens ST200611 [13], being the second time that this class of supposedly exclusive marine natural products were isolated from these myxobacteria, after the isolation and characterization in 2012 by Crews et al. of bengamides E (5), F (6) and E’ (7) from a similar specimen of Myxococcus virescens [12]. Interestingly, in the relevant contribution of Brönstrup, their authors deciphered the genetic blueprint for the biosynthesis of the bengamides, identifying a polyketide synthase (PKS)/nonribosomal peptide synthetase (NRPS) hybrid system as the responsible for the biosynthesis. Accordingly, the biosynthetic proposal was that an isobutyryl-CoA starter unit was sequentially assembled with a malonyl-CoA, two glycolate units and, finally, a L-lysine residue. After reductive processes of the resulting polyketide, O-methylation and a lactamization process, the resulting natural products are produced, which were optionally further N-methylated at the caprolactam moiety.
Additionally, the authors disclosed that two copies of methionine aminopeptidases (MetAP1a and MetAP1b) were encoded, whose sequence analyses revealed the presence of a leucine residue in position 154 in contrast to the cysteine or alanine residues present in other prokaryotic and eukaryotic MetAPs, which might explain the resistance that the MetAPs, produced by these myxobacterial, present to the biosynthesized bengamides. On the other hand, the identification of the biosynthetic pathway lets the authors exploit these myxobacterial strains for the production of bengamides and analogues by fermentation. In fact, the bengamide analogues 29–33 were prepared by semisynthesis from natural bengamide E’ (7) via N-alkylation of its per-acetylated derivative (Scheme 1a). The biological evaluation of these analogues against a HCT116 tumoral cell line, revealed potent antitumoral activities in the nM range. In pursuit of more potent analogues with potential clinical applications, the authors prepared by total synthesis a series of fused benzocaprolactam derivatives 36–41 (Scheme 1b), whose biological evaluation against a panel of 14 cancer cell lines furnished excellent results, being the analogues 36 and 39 the most active (Table 2). For the synthesis of these derivatives, the authors employed the synthesis developed by Kinder [27], according to which lactone 34 was reacted with the amino benzocaprolactames 35a–f in the presence of sodium 2-ethylhexanoate to furnish the final bengamide derivatives in 30–55% yields. Analysis of their pharmacokinetic properties showed that these compounds were stable in plasma and had low metabolic labilities when subjected to mouse, rat and human liver microsomes. Furthermore, compound 36 displayed moderate clearance and volume of distribution, a terminal half-life of 3.4 h and a solubility of 370 μM at pH 7.4. An in vivo study of this compound 36 with female C57BL/6 mice bearing early-stage B16 melanoma determined that in the highest nontoxic dose, established at 60 mg/kg per injection, with a total dose of 480 mg/Kg, the antitumor activity was of a 31% for the tumor/control value.
Based on the excellent and striking antitumor properties of some of the described analogues, in our research group, we decided to evaluate the viability of one of their most potent analogues described so far, analogue 28, against colorectal cancer (CRC) cell lines as a new alternative treatment of colon cancer [35]. A preliminary antitumor evaluation against different tumor and non-tumor cell lines revealed this analogue as a very potent antitumor compound in the low micromolar range, although not so potent as previously described by Nan et al. (Table 3). In addition, it was important to stand out the IC50 of 28 against the CCD18 normal colon cell line, which proved to be a 70-fold higher concentration in comparison with the IC50 against the T84 and SW480 colon cancer cell lines. This is an indication of a low toxicity of 28 in normal cells compared to tumor cells. In fact, the toxicity of this analogue was evaluated by means of a hemolysis test using human erythrocytes, detecting a very low level of hemolysis at the highest doses of this compound, not causing erythrocyte agglutination, which implies a lack of hemotoxicity. Similarly, an absence of toxicity was confirmed against white blood cells and macrophages, representing a promising option for the treatment of CRC due to its great biocompatibility with blood cells, including cells of the immune system. Currently, we are conducting in vivo studies with this analogue that will allow us to define and determine the potential viability of this compound for its clinical use.
Among the new analogues prepared in the last years, Pham and coworkers have described the preparation of epimers at the caprolactam moiety, which surprisingly proved to be more potent against different tumor cell lines compared with the derivatives with the configuration of the natural products [47]. Thus, after the demonstration that changes of the stereochemistries at the polyketide chain, through the 2-, 2,3- and 3,4-epimers (42–44) and the enantiomer of bengamide E [48], resulted in almost complete loss of antitumor activities, the 2′-epimer of bengamide E, analogue 45, exhibited more potent cytotoxicity against six cancer cell lines, namely KB (mouth epidermal carcinoma cells), HepG2 (human liver hepatocellular carcinoma cells), LU (human lung adenocarcinoma cells), MCF7 (human breast cancer cells), HL60 (human promyelocytic leukemia cells) and HeLa (human cervical carcinoma cells), compared with the natural bengamide E (5). Similar observations were obtained with the 2′R analogues 47 and 48, including the N-substituted caprolactam series 54b–56b, including an interesting selectivity against some cancer cell lines, such compounds 45 or 55b, which selectively inhibited MCF-7 cells, while 54b or 56b displayed a major selectivity toward Lu-1 and HepG-2 cell lines, respectively, with some of them with IC50 values less than 1 μM [49].
On the other hand, the corresponding [6]-membered ring derivatives 50–53 displayed in general less antitumor activities compared with the [7]-membered caprolactam ring counterparts (Figure 4 and Table 4).
From a synthetic point of view, it is interesting to stand out that all these bengamide analogues were prepared by coupling the lactone 57 with a collection of 19 amines (58) with the assistance of microwave irradiation instead of conventional basic conditions, to smoothly afford the resulting amides in reasonable and reproducible yields (Scheme 2).

2.2. Antifungal Activities of the Bengamides

The biological screening of the bengamides showed that these compounds were inactive against fungi, including Candida albicans and Saccharomyces braziliensis. Conversely, the bengazoles, which are the second most common secondary metabolites found in Jaspis species (Figure 5), stand out for their antifungal activity against Candida albicans [50,51], displaying comparable values of inhibition with amphotericin B and with a similar mode of action [52]. In a recent study conducted by Molinski et al. [53], it was found a synergistic activity of a mixture of bengamide A (1) and bengazoles A–G (59a–g). In fact, it was observed that while pure bengazoles presented a MIC value of 1 μM against C. albicans at 0.5 μg/disk, inducing a zone of inhibition of 9–10 mm, a sample containing a mixture of bengazoles and bengamides produced a larger inhibition zone of 40 mm. Particularly, in such studies, a mixture of bengazoles A–G, at a constant loading of 0.5 μg/disk, and variable amounts of bengamide A (1) were combined and tested against Candida albicans ATCC14503. Unexpectedly, in a mass ratio of 400:1 for 1:59, complete inhibition of the antifungal activity of 59 was detected. Then, when the concentrations of bengamide A (1) were lowered, a dose-dependent response was observed, finding out that in a 2:1 ratio of 1:59 the zone of inhibition increased a 50%, confirming a synergy between both natural products.

2.3. Antiviral Activity of the Bengamides

In a recent campaign for the discovery of HIV-1 inhibitors from marine natural products, the Brockman’s group has demonstrated for the first time the potential of bengamide A (1) as a new antiviral agent, by inhibition of the NF-kB-dependent HIV-1 replication [54]. Importantly, this study represents the first report of antiviral activity of bengamides, identifying bengamide A as the most potent natural product as a NF-kB inhibitor to modulate HIV-1 replication [55]. Thus, the screening of 252 pure compounds derived from marine invertebrates and microorganisms, through a multicycle HIV-1 replication assay, identified bengamide A (1) as the most potent inhibitor, with an activity of EC50 around 15 nM, an activity which is comparable to common antiretrovirals such as indinavir, efavirenz and raltegravir. Furthermore, these biological studies revealed that the HIV-1 inhibition by bengamide A (1) was not primarily attributable to its cytotoxicity, but this inhibitory capacity was mediated by its effect in the NF-κB-dependent viral gene expression, preventing transcription of HIV downstream of RNA viral reverse transcription and integration. Anyway, as pointed out by the authors, it was not excluded that bengamide A (1) could interfere with other steps of the viral replication cycle, which is currently under investigation.

3. Development of the Bengamides and Their Analogues as New Antibiotics

As mentioned in the Introduction Section, the preliminary biological evaluations of the bengamides, accomplished by Crews, demonstrated that bengamides A (1) and B (2) exhibited antibiotic activities against Streptococcus pyrogenes. However, no more biological studies were achieved in this direction until 2011 when Ye et al. confirmed the ability of the bengamides to inhibit MetAp of Mycobacterium tuberculosis [56]. Taking into account that methionine aminopeptidases are ubiquitous enzymes either in eukaryotic or prokaryotic cells, it was proved that these enzymes are essential for bacteria, leading to their death when MetAP gene is deleted [57]. Importantly, despite that all MetAPs are homologous in sequence in the catalytic domain, mammalian MetAPs present an extension at the N-terminus. Although this N-terminal extension in human MetAPs is not required for enzyme activity, it could present an important impact on the interaction of the enzyme with inhibitors, and this difference could be exploited for selective inhibition of the MetAP of bacteria over the human MetAPs. Thus, in the particular case of the MetAP of Mycobacterium tuberculosis, there are two genes (mapA and mapB in the H37Rv genome and map_1 and map_2 in the CDC1551 genome) that express MtMetAP1a and MtMetAP1c, respectively. In the case of MtMetAP1c, this protein was purified, and its structural analysis revealed an SH3 binding motif in its N-terminus. On the other hand, the MtMetAP1a is shorter at the N-terminus and has no such SH3 binding motif. In both MetAPs, the active site of the enzyme is a pocket with a hydrophobic environment where is situated a divalent metallic ion such as Mn, Fe, Co or Ni. Next to the pocket hole is situated a mobile hydrophobic loop whose interaction with the substrate is believed to be weak, but not clear if there is an actual interaction [58].
In this way, most residues in the active site pockets of MetAPs of both prokaryotic and eukaryotic origin are conserved. However, at the opening and outside of the pocket, more structural variations exist because of the various lengths and residues in the N-terminal extension, opening the possibility of exploring additional interactions that could potentially differentiate the inhibition potency between the bacteria and mammalian peptidases [59]. According to the molecular framework of the bengamides and, taking into account their mode of interaction at the active site of the MetAPs, structural modifications that could modulate the selectivity in the inhibition should be done in the amide fragment, replacing the caprolactam moiety by various amide moieties that could generate additional interactions to display inhibition against tubercular MetAPs and weak or no inhibition of human MetAPs. Aiming to find high inhibition potency and selectivity against different cell MetAPs, the Ye group achieved the synthesis of a set of seven analogues 60–66, which were evaluated as potential antitubercular agents (Figure 6) [56].
In these biological evaluations, their inhibitions were measured against purified MtMetAP1a and MtMetAP1c, which were activated by divalent metal ions including CoII, MnII, NiII and FeII [60]. For therapeutic applications, it is crucial that the inhibition assays are done in its native metalloform because inhibitors can display marked variations in inhibitory potency toward different metalloforms of the enzyme, as has been demonstrated in studies with E. coli MetAP [61,62,63]. According to the obtained results, as summarized in Table 5, compounds bearing aromatic rings (60, 61 and 66) showed remarkable potencies toward the CoII, MnII and FeII forms of MtMetAP1a, probably due to additional interactions of the aromatic systems.
The obtention of crystals of the complexes of MtMetAP1a with either 65 or 66 let the obtention of the X-ray structures, confirming that both inhibitors interact in the same way as bengamides with human type 2 MetAP, according to which the triol system coordinates with the two active site metal ions, and the tert-butyl alkene chain occupies the P1 pocket through a hydrophobic interaction [64]. In the case of 65, in which the amide moiety is shorter, this fragment takes a position similar to that of the caprolactam ring of the bengamides. Interestingly, the trimethylphenyl group of 66 is embedded in the shallow cavity at the opening present, particularly in the MetAP of the M. tuberculosis. In addition, these inhibitory activities were associated with an antitubercular activity, being analog 66 the most active against both replicating M. tuberculosis with a MIC value of 50.6 μM (comparatively, rifampin has a MIC value of 0.08 μM and isoniazid with a MIC value of 0.24 μM) and non-replicating M. tuberculosis with a MIC value of 107.4 μM (comparatively, rifampin has a MIC value of 1.96 μM and isoniazid with a MIC value of >128 μM) (In these studies MIC values were defined as the percent inhibitions at 128 μM or as the lowest concentration, effecting a decrease of ≥0% in fluorescence or luminescence assays relative to untreated controls).
For the development of some of these analogues as new antitubercular agents, it is essential to minimize inhibition of human MetAPs to decrease of this way the toxicity. To assess the potential toxicity of these analogues, their effects on the growth of human K562 cells were evaluated with the result that analogues 62, 63, 64 and 65 displayed no or weak activity, being 66 the most active against the growth of these human cancer cells. These results demonstrated that the selectivity of these bengamide-based antibiotics required to be significantly improved.
Following these pioneering studies of Yu et al., as part of a research programme directed towards the identification of new leads against M. tuberculosis, 1434 diverse marine extracts were screened for their ability to inhibit M. tuberculosis growth in vitro [65]. From this extensive screening, 18 extracts, 11 from the Porifera phylum and 5 from the Chordata phylum, were identified with the ability to inhibit the growth of M. tuberculosis in a 50-0.39 μg/mL range for MIC50, defined as the concentration that resulted in 50% survival of bacteria in comparison to untreated controls. Among all these extracts, two samples from Porifera derived from a Tedania sp. sea sponge from Queensland in Australia, displayed outstanding MIC50 values of 0.39 and 1.56 μg/mL, respectively. The purification of the active ingredients of both extracts led to the identification of bengamide B (2) as the responsible for this antitubercular activity. Having bengamide B (2) in hand, the authors evaluated its inhibitory capacity against purified MetAP enzymes derived from M. tuberculosis (MtMeAP1c), E. faecalis (EfMeAP1b) and human MetAP (HsMeAP1b), proving to be a highly potent inhibitor for the three enzymes with inhibition percentages of 72.84, 83.33 and 84.72%, respectively at a single concentration of 50 μM of bengamide B (2). For the particular case of EfMeAP1b, it was possible to check that, despite its strong inhibition of this enzyme, this activity was not reflected in bacterial inhibition in vitro studies against E. faecalis.
On the other hand, despite its inhibition against human MetAP (HsMeAP1b), bengamide B (2) did not result in cytotoxic against different human cells, including THP-1, HepG2, HEK293 and A549. More interesting and fruitful was the study of combination therapy against tuberculosis (TB) by use of bengamide B (2). Accordingly, a combined therapy consisting of bengamide B (2) and rifampicin against M. tuberculosis H37Rv revealed a strong synergy according to the Chou–Talalay combination index (CI), which was 0.1–0.3, allowing for a dose reduction index (DRI) from 8-fold to over 200-fold for rifampicin and 3-fold to over 14-fold for bengamide B (2).
More recently, Nan et al., who designed, synthesized and evaluated a wide library of ring-opened bengamide analogues as antitumor agents, paid attention to the development of new antibacterial compounds based on bengamides [66]. To this aim, they synthesized a first library of the new ring-opened bengamide analogues 68a–f by coupling the key precursors 57 and 67a–f, according to the synthetic route depicted in Scheme 3. This set of compounds was then tested against Staphylococcus aureus, strain 8325-4, resulting active enough according to the MIC values obtained, as indicated in Scheme 3. This biological evaluation was then extended to the following S. aureus strains, including S. aureus clpP mutant strain (ΔclpP), S. aureus clpP complementary strain (ΔclpP::clpP) and the 8325-4 strain overexpressing clpP (OEclpP). These bacteria strains are characterized by overexpressing the protease caseinolytic protease P (ClpP) [67], which is an energy-dependent serine protease, which plays an essential role in bacterial pathogenesis [68].
These proteases are actually present in either bacteria or in eukaryotes and allow the cell to maintain proteostasis by controlling the degradation of undesired proteins from the intracellular environment, including those involved in regulating stress responses and virulence factor production. In the case of S. aureus, it was well established that S. aureus ClpP (SaClpP) regulates bacterial virulence and pathogenesis, playing a critical role in infectivity and virulence during host infection. Not surprisingly, ClpP has attracted the interest of the medicinal chemistry community as a novel valid target for antibiotic discovery. As a consequence, small molecules have been described capable of dysregulating the function of ClpP, towards either its inhibition or activation, which leads to a bactericidal activity [69]. In the particular case of ClpP activators, their effect is the bacteria inhibition or death [70], whereas ClpP inhibitors produce a decrease in bacterial virulence [71]. Thus, the first ClpP activators corresponded to the named acyldepsipeptides ADEPs, such as ADEP-1 or ADEP-4, whose discovery was the result of a high-throughput screening study [72,73]. As a consequence of the ClpP activation, the process of protein degradation is out of control, affecting unfolded not only proteins but also nascent proteins, which triggers the inhibition of cell division and eventually cell death. Interestingly, when the bengamide analogues were evaluated against the aforementioned ClpP-related strains of S. aureus, some of them, such as 68a, showed potent activity against OEclpP strain with a MIC value of 0.78–1.56 μg/mL, which could be an indication that bengamides might activate direct or indirectly ClpP.
In order to increase the antibiotic activity of this class of bengamide analogues, further structural optimization was accomplished by modifying the size of the terminal rings and by replacement of the ester group with a linear alkynyl motif to improve biological stability due to the known instability and sensitivity of the esters to the metabolism [74]. This structural optimization led to compound type 69, and then the second generation of ring-opened bengamide analogues was prepared by modification of the methyl group corresponding to the alanine residue by different alkyl and aryl groups (69a–f) (Figure 7).
The biological evaluation against the different strains of S. aureus of this second series revealed that compounds 69a and 69f, with MIC values of 1.56–3.13 and 6.25–12.5 μg/mL, respectively, were able to activate ClpP to degrade α-casein [75], being compound 69f more active for SaClpP activation. Then, the third round of optimization was achieved by changing the para-fluorine group contained in compound 69a to various substituents at different sites on the phenyl ring, preparing the series of compounds 70a–l. From this new library of bengamide analogues, compound 70i (MIC = 6.25–12.5 μg/mL) displayed moderate activity for SaClpP activation in vitro. Finally, the SaClpP activation and antibacterial activity observed in compounds 69f and 70i allowed the authors to design and synthesize compound 71, which displayed activation on the degradation of protein substrate by SaClpP with an EC50 of 3.13–6.25 μM, while was still active against S. aureus in a ClpP-dependent manner (Figure 7). Therefore, the authors proved that bengamide analogues might potentially act as a new class of antibiotics by targeting the S. aureus ClpP protease.
As a continuation of the research previously described, one year later, Nan and co-workers reported the synthesis of a new series of ring-opened bengamide analogues [76] in order to improve the antibacterial activity displayed by the analogue 68a and to explore the antibiotic potential against methicillin-resistant Staphylococcus aureus (MRSA), which represents a real threat for the human health as current antibiotics are no longer effective against these bacteria [77]. Thus, taking 68a as the hit compound, they synthesized a total of twenty-four bengamide analogues with opened rings (72a–g, 73a–m and 74–76) (Figure 8) in two phases. In the first phase, they prepared the series 72a–g to assess the contribution of the alanine residue to the anti-MRSA activity by replacement of the methyl group with different alkyl groups and by the change of the stereochemistry at this position. To this aim, these compounds were tested against six different kinds of MRSA, namely USA300, NRS-1, NRS-70, NRS-271, NRS-108 and NRS-100, and using vancomycin (Van) and tetracycline (Tetra) as reference drugs (Table 6).
The biological results of this study reflected that the replacement of the methyl group of L-alanine did not improve in any case the anti-MRSA activity. In light of these results, the authors decided to keep the L-alanine residue and, then explore the effect of the ester group on the antibacterial activity. In this second phase, the first set of 7 different esters 73a–g, were prepared, and it was proved, after the corresponding biological evaluations, that bulky aliphatic groups presented a beneficial impact in their anti-MRSA activities. These interesting results encouraged the authors to prepare the adamantyl derivatives 73h–m as a suitable and rational choice. From this study, the authors identified 73j as the most potent analogue, with MIC values against the different MRSA strains in the 0.04–0.31 μg/mL range.
Given the poor stability of the ester functional group in organisms, the corresponding amide 74 was synthesized and biologically evaluated. However, to the dismay of the authors, this compound was much less potent than its ester analogue, with a MIC value of 2.0–4.0 μg/mL, which indicated that the ester group seemed to be crucial for the anti-MRSA activity. Similarly, the terminal olefin analogue 75 and the reduction product 76 were prepared, but their biological activities against MRSA remarkably decreased, being their MIC values of >50 and 1.00–8.00 μg/mL, respectively (Table 6). Therefore, given the excellent antibacterial activity of the adamantane ethanol ester derivative 73j towards the six Staphylococcus aureus strains previously cited, its pharmacokinetic parameters were evaluated by means of an in vivo assay, according to which 73j was provided to mice via oral or intraperitoneal administrations in doses of 100 mg/Kg. The analysis of peripheral blood at different times showed that 73j was hydrolysed to its corresponding acid from the beginning. This poor stability in mouse plasma was ascribed to the high levels of carboxylesterases. In contrast, 73j displayed great stability in human plasma and kept its anti-MRSA activity with a MIC of 0.5 μg/mL on the USA300 strain. In addition, compound 73j did not exhibit inhibitory activity against hERG (IC50 > 40 μmol/L), which is a promising indication of clinical safety.
Finally, as mentioned in the Introduction section, very recently, a new member of the bengamides, bengamide R (19), was isolated and characterized from Jaspis splendens sponges, collected in Mauritius, as part of a research programme directed towards the discovery and identification of new antimycobacterial agents from marine sources [16]. Due to the severity of tuberculosis (TB), caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb strains, the development of effective therapies is urgently needed, and as a consequence, the search and identification of new anti-TB agents are required [78]. Given the impressive and extensive source of bioactive metabolites that represents marine organisms [79], the authors decided to tackle an extensive screening, in which a wide variety of 984 marine invertebrate extracts were evaluated, detecting two extracts against Mycobacterium tuberculosis corresponding to the sponges Hyrtios reticulatus and Jaspis splendens as the most active with MIC90 (Minimum concentration in μg/mL to inhibit the growth of the bacteria a 90%) values of 51 and 2.4 μg/mL, respectively. While for the Hyrtios extract, its activity was associated with the natural product heteronemin [80,81], for the Jaspis extract, it was demonstrated that the responsibility for the antimycobacterial activity was the bengamides P (17) and Q (18), which were isolated and purified from this extract. These results provide more evidence of the potential of the bengamides as promising new antibiotics and, in particular, as novel antituberculosis leads.

4. Conclusions

The discovery, structural elucidation and biological properties of the bengamides, a family of natural products isolated from Jaspis sponges and also from the terrestrial myxobacteria Myxococus virescens, elicited intense research activity, attracting the interest of chemists and biologists alike during the last decades due to their potent antitumor properties with a fumagillin-like mechanism of action by inhibition of the methionine aminopeptidases. As amply demonstrated in the literature, bengamides are a very interesting family of natural products with an outstanding biological profile, which includes not only potent antitumoral activity but also antihelmintic, antiviral and antibiotic activities. The manifold value of the bengamides, together with their unique mechanism of action and unprecedented molecular architectures, has positioned them as excellent targets in medicinal chemistry and have provided great opportunities in this field. As a consequence, enormous efforts from different research groups around the world have been made directed towards their total synthesis, design of new analogues and biological evaluations, involving around more than 150 synthetic bengamide analogues up to date.
Overall, this investigation led to important new insights and useful structure-activity relationships within the bengamide family that allowed for the identification of new chemical entities with powerful potencies and improved pharmacological properties beyond those of the naturally occurring bengamides. Interestingly, in recent years, the potential of the bengamides as antibiotics has been explored and investigated, being witnessing an evolution of the bengamides from their initial consideration as antitumor agents up to their current status as promising antibiotics. In this review, we had reported the recent progress in this new direction of the bengamides, together with the new advances in the antitumoral, antifungal and antiviral properties of these enticing molecules since 2014, when we reported an extensive review of these natural compounds.
In this sense, the growing emergence of drug-resistant bacteria strains and the lack of new antibiotics is currently one of the most serious problems in human health. Thus, the search for new antibiotics must become a maximum priority for the scientific community. The new discovery of the bengamides as potential antibiotics opens promising opportunities in the future that might deal with this urgent problem. However, although massive investigations have been devoted to the begamides, still persistent research has to be carried out to position bengamide analogue candidates in the clinic, and this must be the priority of medicinal chemistry research groups in the incoming years.

Author Contributions

Conceptualization, F.S., I.C.-S. and C.P.-A.; Writing—Original Draft Preparation, C.P.-A., F.M.-U., M.G.-C., A.S.-R., I.C.-S. and F.S.; writing—review and editing, J.M.L.-R., M.S.P.-G., A.D.-M., S.K., D.W.W., J.P., C.M., I.C.-S. and F.S. All authors have read and agreed to the published version of the manuscript.

Funding

Supported by grants RTI2018-098296-BI00 (Ministerio de Ciencia e Innovación), PI19/01478 from Instituto de Salud Carlos III (ISCIII) (FEDER), P20_00540 (Andalusian Government and FEDER), K99GM138758 and R35GM136286 (National Institute of General Medical Sciences of the National Institutes of Health), A-CTS-666-UGR20 (University of Granada) (FEDER), CTS-107 (Andalusian Government) and 2021-GRIN-30998 (University of Castilla-La Mancha).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

C.P.-A. thanks to the Ministerio de Educación, Cultura y Deporte for a predoctoral fellowship (FPI programme). F.M.-U. and M.G.-C. thank to the University of Málaga for research contracts corresponding to the research programme of the university (Plan Propio).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. García-Ruiz, C.; Sarabia, F. Chemistry and biology of bengamides and bengazoles, bioactive natural products from Jaspis sponges. Mar. Drugs 2014, 12, 1580–1622. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Quiñoá, E.; Adamczeski, M.; Crews, P.; Bakus, G.J. Bengamides, heterocyclic anthelminthics from a Jaspidae marine sponge. J. Org. Chem. 1986, 51, 4494–4497. [Google Scholar] [CrossRef]
  3. Adamczeski, M.; Quiñoá, E.; Crews, P. Novel sponge-derived amino acids. 5. Structures, stereochemistry, and synthesis of several new heterocycles. J. Am. Chem. Soc. 1989, 111, 647–654. [Google Scholar]
  4. Thale, Z.; Kinder, F.R.; Bair, K.W.; Bontempo, J.; Czuchta, A.M.; Versace, R.W.; Phillips, P.E.; Sanders, M.L.; Wattanasin, S.; Crews, P. Bengamides revisited: New structures and antitumor studies. J. Org. Chem. 2001, 66, 1733–1741. [Google Scholar] [CrossRef] [PubMed]
  5. Rudi, A.; Kashman, Y.; Benayahu, Y.; Schleyer, M. Amino acid derivatives from the marine sponge Jaspis digonoxea. J. Nat. Prod. 1994, 57, 829–832. [Google Scholar] [CrossRef]
  6. DʼAuria, M.V.; Giannini, C.; Minale, L.; Zampella, A.; Debitus, C.; Frostin, M. Bengamides and related new amino acid derivatives from the new caledonian marine sponge Jaspis carteri. J. Nat. Prod. 1997, 60, 814–816. [Google Scholar] [CrossRef]
  7. Groweiss, A.; Newcomer, J.J.; OʼKeefe, B.R.; Blackman, A.; Boyd, M.R. Cytotoxic metabolites from an Australian collection of the sponge Jaspis species. J. Nat. Prod. 1999, 62, 1691–1693. [Google Scholar] [CrossRef]
  8. Fernández, R.; Dherbomez, M.; Letourneux, Y.; Nabil, M.; Verbist, J.F.; Biard, J.F. Antifungal metabolites from the marine sponge Pachastrissa sp.: New bengamide and bengazole derivatives. J. Nat. Prod. 1999, 62, 678–680. [Google Scholar] [CrossRef]
  9. Pettit, G.R.; Hogan, F.; Xu, J.-P.; Tan, R.; Nogawa, T.; Cichacz, Z.; Pettit, R.K.; Du, J.; Ye, Q.-H.; Cragg, G.M.; et al. Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants and microorganisms. J. Nat. Prod. 2008, 71, 438–444. [Google Scholar] [CrossRef]
  10. Ovenden, S.P.B.; Nielson, J.L.; Liptrot, C.H.; Willis, R.H.; Tapiolas, D.M.; Wright, A.D.; Motti, C.A. A new diketopiperazine, cyclo-(4-S-hydroxy-R-proline-R-isoleucine), from an australian specimen of the sponge Stelletta sp. Mar. Drugs 2011, 9, 2469–2478. [Google Scholar] [CrossRef]
  11. Susilowati, F.; Swasono, R.T.; Okino, T.; Haryadi, W. In vitro cytotoxic anticancer potential of bioactive fraction isolated from indonesian tidal sponge Calthropella sp. Asian J. Pharm. Clin. Res. 2019, 12, 380–383. [Google Scholar] [CrossRef] [Green Version]
  12. Johnson, T.A.; Sohn, J.; Vaske, Y.M.; White, K.N.; Cohen, T.L.; Vervoot, H.C.; Tenney, K.; Valeriote, F.A.; Bjeldanes, L.F.; Crews, P. Myxobacteria versus sponge-derived alkaloids: The bengamide family identified as potent immune modulating agents by scrutiny of LC-MS/ELSD libraries. Bioorg. Med. Chem. Lett. 2012, 20, 4348–4355. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Wenzel, S.C.; Hoffmann, H.; Zhang, J.; Debussche, L.; Haag-Ritcher, S.; Kurz, M.; Nardi, F.; Lukat, P.; Kochems, I.; Tietgen, H.; et al. Production of the bengamide class of marine natural products in Myxobacteria: Biosynthesis and structure-activity relationships. Angew. Chem. Int. Ed. 2015, 54, 15560–15564. [Google Scholar] [CrossRef] [PubMed]
  14. McCauley, E.; Radjasa, O.K.; Trianto, A.; Crews, M.S.; Smith, A.; Smith, G.C.; Zerebinski, P.; Sabdono, A.; Crews, P. The UNDIP-UCSC campaign to culture chemically prolifix gram-negative bacteria from Jaspis sponges. Arkivoc 2018, 4, 123–131. [Google Scholar] [CrossRef] [Green Version]
  15. Carballeira, N.; Thompson, J.E.; Ayanoglu, E.; Djerassi, C. Biosynthetic studies of marine lipids. 5. The biosynthesis of long-chain branched fatty acids in marine sponges. J. Org. Chem. 1986, 51, 2751–2756. [Google Scholar] [CrossRef]
  16. Acquah, K.S.; Beukes, D.R.; Seldon, R.; Jordaan, A.; Sunassee, S.N.; Warner, D.F.; Gammon, D.W. Identification of antimycobacterial natural products from a library of marine invertebrate extracts. Medicines 2022, 9, 9. [Google Scholar] [CrossRef]
  17. Adamczeski, M.; Quiñoá, E.; Crews, P. Novel sponge-derived amino acids. 11. The entire absolute stereochemistry of the bengamides. J. Org. Chem. 1990, 55, 240–242. [Google Scholar] [CrossRef]
  18. Phillips, P.E.; Bair, K.W.; Bontempo, J.; Crews, P.; Czuchta, M.; Kinder, F.R.; Versace, R.W.; Wang, B.; Wang, J.; Wood, A.; et al. Bengamide E arrests cells at the G1/S restriction point and within the G2/M phase of the cell cycle. Proc. Am. Assoc. Cancer Res. 2000, 41, 59. [Google Scholar]
  19. Towbin, H.; Bair, K.W.; DeCaprio, J.A.; Eck, M.J.; Kim, S.; Kinder, F.R.; Morollo, A.; Mueller, D.R.; Schindler, P.; Song, H.K.; et al. Proteomics-based target identification: Bengamides as a new class of methionine aminopeptidase inhibitors. J. Biol. Chem. 2003, 278, 52964–52971. [Google Scholar] [CrossRef] [Green Version]
  20. Hu, X.; Dang, Y.; Tenney, K.; Crews, P.; Tsai, C.W.; Sixt, K.M.; Cole, P.A.; Liu, J.O. Regulation of c-Src nonreceptor tyrosine kinase activity by bengamide A through inhibition of methionine aminopeptidases. Chem. Biol. 2007, 14, 764–774. [Google Scholar] [CrossRef] [Green Version]
  21. Griffith, E.C.; Su, Z.; Niwayama, S.; Ramsay, C.A.; Chang, Y.H.; Liu, J.O. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc. Natl. Acad. Sci. USA 1998, 95, 15183–15188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Griffith, E.C.; Su, Z.; Turk, B.E.; Chen, S.; Chang, Y.H.; Wu, Z.; Biemann, K.; Liu, J.O. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 1997, 4, 461–471. [Google Scholar] [CrossRef] [Green Version]
  23. Joharapurkar, A.A.; Dhanesha, N.A.; Jain, M.R. Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. Diabetes Metab. Syndr. Obes. Targets Ther. 2014, 7, 73–84. [Google Scholar] [CrossRef] [Green Version]
  24. Sashidhara, K.V.; White, K.N.; Crews, P. A selective account of effective paradigms and significant outcomes in the discovery of inspirational marine natural products. J. Nat. Prod. 2009, 72, 588–603. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Kim, S.; LaMontagne, K.; Sabio, M.; Sharma, S.; Versace, R.W.; Yusuff, N.; Phillips, P.E. Depletion of methionine aminopeptidase 2 does not alter cell response to fumagillin and bengamides. Cancer Res. 2004, 64, 2984–2987. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Yin, S.-Q.; Wang, J.-J.; Zhang, C.-M.; Liu, Z.-P. The development of MetAp-2 inhibitors in cancer treatment. Curr. Med. Chem. 2012, 19, 1021–1035. [Google Scholar] [CrossRef] [PubMed]
  27. Kinder, F.R., Jr.; Versace, R.W.; Bair, K.W.; Bontempo, J.M.; Cesarz, D.; Chen, S.; Crews, P.; Czuchta, A.M.; Jagoe, C.T.; Mou, Y.; et al. Synthesis and antitumor activity of ester-modified analogues of bengamide B. J. Med. Chem. 2001, 44, 3692–3699. [Google Scholar] [CrossRef]
  28. Xu, D.D.; Waykole, L.; Calienni, J.V.; Ciszewski, L.; Lee, G.T.; Liu, W.; Szewczyk, J.; Vargas, K.; Prasad, K.; Repi, O.; et al. An expedient synthesis of LAF389, a bengamide B analogue. Org. Process. Res. Dev. 2003, 7, 856–865. [Google Scholar] [CrossRef]
  29. Dumez, H.; Gall, H.; Capdeville, R.; Dutreix, C.; van Oosterom, A.T.; Giaccone, G. A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. Anti-Cancer Drugs 2007, 18, 219–225. [Google Scholar] [CrossRef]
  30. Sarabia, F.; Sánchez-Ruiz, A. A diversity-oriented synthetic approach to bengamides. Tetrahedron Lett. 2005, 46, 1131–1135. [Google Scholar] [CrossRef]
  31. Sarabia, F.; Sánchez-Ruiz, A. Total synthesis of bengamide E and analogues by modification at C-2 and at terminal olefinic positions. J. Org. Chem. 2005, 70, 9514–9520. [Google Scholar] [CrossRef] [PubMed]
  32. Sarabia, F.; Martín-Gálvez, F.; Chammaa, S.; Martín-Ortiz, L.; Sánchez-Ruiz, A. Chiral sulfur ylides for the synthesis of bengamide E and analogues. J. Org. Chem. 2010, 75, 5526–5532. [Google Scholar] [CrossRef] [PubMed]
  33. Martín-Gálvez, F.; García-Ruiz, C.; Sánchez-Ruiz, A.; Valeriote, F.A.; Sarabia, F. An array of bengamide E analogues modified at the terminal olefinic position: Synthesis and antitumor properties. ChemMedChem 2013, 8, 819–831. [Google Scholar] [CrossRef] [PubMed]
  34. Sarabia, F.; Martín-Gálvez, F.; García-Ruiz, C.; Sánchez-Ruiz, A.; Vivar-García, C. Epi-, epoxy-, and C2-modified bengamides: Synthesis and biological evaluation. J. Org. Chem. 2013, 78, 5239–5253. [Google Scholar] [CrossRef]
  35. García-Pinel, B.; Porras-Alcalá, C.; Cabeza, L.; Ortiz, R.; Prados, J.; Melguizo, C.; Cheng-Sánchez, I.; López-Romero, J.M.; Sarabia, F. Bengamide analogues show a potent antitumor activity against colon cancer cells: A preliminary study. Mar. Drugs 2020, 18, 240. [Google Scholar] [CrossRef]
  36. White, K.N.; Tenney, K.; Crews, P. The bengamides: A mini-review of natural sources, analogues, biological properties, biosynthetic origins and future prospects. J. Nat. Prod. 2017, 80, 740–755. [Google Scholar] [CrossRef]
  37. Liu, G.; Ma, Y.M.; Tai, W.Y.; Xie, C.M.; Li, Y.L.; Li, J.; Nan, F.J. Design, synthesis, and biological evaluation of caprolactam-modified bengamide analogues. ChemMedChem 2008, 3, 74–78. [Google Scholar] [CrossRef]
  38. Alam, S.; Dhimane, H. A concise synthesis of bengamide E and analogues via E-selective cross-metathesis olefination. Synlett 2010, 19, 2923–2927. [Google Scholar]
  39. Tai, W.Y.; Zhang, R.T.; Ma, Y.M.; Gu, M.; Liu, G.; Li, J.; Nan, F.J. Design, synthesis, and biological evaluation of ring-opened bengamide analogues. ChemMedChem 2011, 6, 1555–1558. [Google Scholar] [CrossRef]
  40. Liu, Q.J.; Li, H.; Chen, S.P.; Zhou, G.C. Synthesis of (3S,4R)-bengamide E. Chin. Chem. Lett. 2011, 22, 505–507. [Google Scholar] [CrossRef]
  41. Zhang, W.; Liang, Q.; Li, H.; Meng, X.; Li, Z. Concise synthesis and antitumor activity of bengamide E and its analogs. Tetrahedron 2013, 69, 664–672. [Google Scholar] [CrossRef]
  42. Kinder, F.R., Jr. Synthetic approaches toward the bengamide family of antitumor marine natural products. A review. Org. Prep. Proc. Int. 2002, 34, 559–583. [Google Scholar] [CrossRef]
  43. Liu, W.; Szewczyk, J.M.; Waykole, L.; Repic, O.; Blacklock, T.J. Total synthesis of bengamide E. Tetrahedron Lett. 2002, 43, 1373–1375. [Google Scholar] [CrossRef]
  44. Boeckman, R.K., Jr.; Clark, T.J.; Shook, B.C. A practical enantioselective total synthesis of the bengamides B, E, and Z. Org. Lett. 2002, 4, 2109–2112. [Google Scholar] [CrossRef]
  45. Boeckman, R.K., Jr.; Clark, T.J.; Shook, B.C. The development of a convergent and efficient enantioselective synthesis of the bengamides via a common polyol intermediate. Helv. Chim. Acta 2002, 85, 4532–4560. [Google Scholar] [CrossRef]
  46. Metri, P.K.; Schiess, R.; Prasad, K.R. Enantiospecific total synthesis of (−)-bengamide E. Chem. Asian J. 2013, 8, 488–493. [Google Scholar] [CrossRef]
  47. Phi, T.D.; Mai, H.D.T.; Tran, V.H.; Truong, B.N.; Tran, T.A.; Vu, V.L.; Chau, V.M.; Pham, V.C. Design, synthesis and cytotoxicity of bengamide analogues and their epimers. Med. Chem. Commun. 2017, 8, 445–451. [Google Scholar] [CrossRef]
  48. Banwell, M.G.; McRae, K.J. A chemoenzymatic total synthesis of ent-bengamide E. J. Org. Chem. 2001, 66, 6768–6774. [Google Scholar] [CrossRef]
  49. Phi, T.D.; Mai, H.D.T.; Tran, V.H.; Vu, V.L.; Truong, B.N.; Tran, T.A.; Chau, V.M.; Pham, V.C. Synthesis of bengamide E analogues and their cytotoxic activity. Tetrahedron Lett. 2017, 58, 1830–1833. [Google Scholar] [CrossRef]
  50. Mulder, R.J.; Shafer, C.M.; Molinski, T.F. First total synthesis of bengazole A. J. Org. Chem. 1999, 64, 4995–4998. [Google Scholar] [CrossRef]
  51. Mulder, R.J.; Shafer, C.M.; Dalisay, D.S.; Molinski, T.F. Synthesis and structure-activity relationships of bengazole A analogs. Bioorg. Med. Chem. Lett. 2009, 19, 2928–2930. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Molinski, T.F. Developments in marine natural products. Receptor-specific bioactive compounds. J. Nat. Prod. 1993, 56, 1–8. [Google Scholar] [CrossRef] [PubMed]
  53. Jamison, M.T.; Wang, X.; Cheng, T.; Molinski, T.F. Synergistic anti-Candida activity of bengazole A in the presence of bengamide A. Mar. Drugs 2019, 17, 102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Tietjen, I.; Williams, D.E.; Read, S.; Kuang, X.T.; Mwimanzi, P.; Wilhelm, E.; Markle, T.; Kinloch, N.N.; Naphen, C.N.; Tenney, K.; et al. Inhibition of NF-κB-dependent HIV-1 replication by the marine natural product bengamide A. Antivir. Res. 2018, 152, 94–103. [Google Scholar] [CrossRef]
  55. Gogineni, V.; Schinazi, R.F.; Hamann, M.T. Role of marine natural products in the genesis of antiviral agents. Chem. Rev. 2015, 115, 9655–9706. [Google Scholar] [CrossRef] [Green Version]
  56. Lu, J.P.; Yuan, X.H.; Yuan, H.; Wang, W.L.; Wan, B.; Franzblau, S.G.; Ye, Q.Z. Inhibition of Mycobacterium tuberculosis methionine aminopeptidases by bengamide derivatives. ChemMedChem 2011, 6, 1041–1048. [Google Scholar] [CrossRef] [Green Version]
  57. Chang, S.Y.; McGary, E.C.; Chang, S. Methionine aminopeptidase gene of Escherichia coli is essential for cell growth. J. Bacteriol. 1989, 171, 4071–4072. [Google Scholar] [CrossRef] [Green Version]
  58. Lu, J.-P.; Yuan, X.-H.; Ye, Q.-Z. Structural analysis of inhibition of Mycobacterium tuberculosis methionine aminopeptidase by bengamide derivatives. Eur. J. Med. Chem. 2012, 47, 479–484. [Google Scholar] [CrossRef] [Green Version]
  59. Luo, Q.-L.; Li, J.-Y.; Liu, Z.-Y.; Chen, L.-L.; Li, J.; Qian, Z.; Shen, Q.; Li, Y.; Lushington, G.H.; Ye, Q.-Z.; et al. Discovery and structural modification of inhibitors of methionine aminopeptidases from Escherichia coli and Saccharomyces Cerevisiae. J. Med. Chem. 2003, 46, 2631–2640. [Google Scholar] [CrossRef]
  60. Lu, J.-P.; Ye, Q.-Z. Expression and characterization of Mycobacterium tuberculosis methionine aminopeptidase type 1a. Bioorg. Med. Chem. Lett. 2010, 20, 2776–2779. [Google Scholar] [CrossRef] [Green Version]
  61. Chai, S.C.; Wang, W.-L.; Ye, Q.-Z. Fe(II) is the native cofactor for Escherichia coli methionine aminopeptidase. J. Biol. Chem. 2008, 283, 26879–26885. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Ye, Q.-Z.; Xie, S.-X.; Huang, M.; Huang, W.-J.; Lu, J.-P.; Ma, Z.-Q. Metalloform-Selective inhibitors of Escherichia coli methionine aminopeptidase and X-ray structure of a Mn(II)-form enzyme complexed with an inhibitor. J. Am. Chem. Soc. 2004, 126, 13940–13941. [Google Scholar] [CrossRef] [PubMed]
  63. Wang, W.-L.; Chai, S.C.; Huang, M.; He, H.-Z.; Hurley, T.D.; Ye, Q.-Z. Discovery of inhibitors of Escherichia coli methionine aminopeptidase with the Fe(II)-form. Selectivity and antibacterial activity. J. Med. Chem. 2008, 51, 6110–6120. [Google Scholar] [CrossRef] [Green Version]
  64. Xu, W.; Lu, J.-P.; Ye, Q.-Z. Structural analysis of bengamide derivatives as inhibitors of methionine aminopeptidases. J. Med. Chem. 2012, 55, 8021–8027. [Google Scholar] [CrossRef] [Green Version]
  65. Quan, D.H.; Nagalingam, G.; Luck, I.; Proschogo, N.; Pillalamarri, V.; Addlagatta, A.; Martinez, E.; Sintchenko, V.; Rutledge, P.J.; Triccas, J.A. Bengamides display potent activity against drug-resistant Mycobacterium tuberculosis. Sci. Rep. 2019, 9, 14396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Kong, X.-Q.; Wei, B.-Y.; Yu, C.-X.; Guan, X.-N.; Ma, W.-P.; Liu, G.; Yang, C.-G.; Nan, F.-J. Design, synthesis and biological evaluation of bengamide analogues as ClpP activators. Chin. J. Chem. 2020, 38, 1111–1115. [Google Scholar] [CrossRef]
  67. Moreno-Cinos, C.; Goossens, K.; Salado, I.G.; Van der Veken, P.; De Winter, H.; Augustyns, K. ClpP protease, a promising antimicrobial target. Int. J. Mol. Sci. 2019, 20, 2232. [Google Scholar] [CrossRef] [Green Version]
  68. Bhandari, V.; Wong, K.S.; Zhou, J.L.; Mabanglo, M.F.; Batey, R.A.; Houry, W.A. The role of ClpP protease in bacterial pathogenesis and human diseases. ACS Chem. Biol. 2018, 13, 1413–1425. [Google Scholar] [CrossRef]
  69. Ye, F.; Li, J.; Yang, C.-G. The development of small-molecule modulators for ClpP protease activity. Mol. BioSyst. 2017, 13, 23–31. [Google Scholar] [CrossRef]
  70. Leung, L.; Datti, A.; Cossette, M.; Goodreid, J.; McCaw, S.E.; Mah, M.; Nakhamchik, A.; Ogata, K.; El Bakkouri, M.; Cheng, Y.Q.; et al. Activators of cylindral proteases as antimicrobials: Identification and development of small molecule activators of ClpP protease. Chem. Biol. 2011, 18, 1167–1178. [Google Scholar] [CrossRef] [Green Version]
  71. Compton, C.L.; Schmitz, K.R.; Sauer, R.T.; Sello, J.K. Antibacterial activity of and resistance to small molecule inhibitors of the ClpP peptidase. ACS Chem. Biol. 2013, 8, 2669–2677. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Brotz-Oesterhelt, H.; Beyer, D.; Kroll, H.P.; Endermann, R.; Ladel, C.; Schroeder, W.; Hinzen, B.; Raddatz, S.; Paulsen, H.; Henninger, K.; et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 2005, 11, 1082–1087. [Google Scholar] [CrossRef] [PubMed]
  73. Malik, I.T.; Brotz-Oesterhelt, H. Conformational control of the bacterial Clp protease by natural product antibiotics. Nat. Prod. Rep. 2017, 34, 815–831. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Hatfield, M.J.; Umans, R.A.; Hyatt, J.L.; Edwards, C.C.; Wierdl, M.; Tsurkan, L.; Taylor, M.R.; Potter, P.M. Carboxylesterases: General detoxyfying enzymes. Chem. Biol. Interact. 2016, 259, 327–331. [Google Scholar] [CrossRef] [Green Version]
  75. Zhang, J.; Ye, F.; Lan, L.; Jiang, H.; Luo, C.; Yang, C.-G. Switching of Staphylococcus aureus Clp protease. J. Biol. Chem. 2011, 286, 37590–37601. [Google Scholar] [CrossRef] [Green Version]
  76. Yu, C.-X.; Wei, B.-Y.; Kong, X.-Q.; Yang, C.-G.; Nan, F.-J. Synthesis and structure-activity relationships of ring-opened bengamide analogues against methicillin-resistant Staphylococcus aureus. Chin. J. Chem. 2021, 39, 671–676. [Google Scholar] [CrossRef]
  77. Lakhundi, S.; Zhang, K. Methicillin-resistant Staphylococcus aureus: Molecular characterization, evolution and epidemiology. Clin. Microbiol. Rev. 2018, 31, e00020-18. [Google Scholar] [CrossRef] [Green Version]
  78. Nguta, J.M.; Appiah-Opong, R.; Nyarko, A.K.; Yeboah-Manu, D.; Addo, P.G.A. Current perspectives in drug discovery against tuberculosis from natural products. Int. J. Mycobacteriol. 2015, 4, 165–183. [Google Scholar] [CrossRef] [Green Version]
  79. Hou, X.; Wang, C.; Gerwick, W.H.; Shao, C. Marine natural products as potential anti-tubercular agents. Eur. J. Med. Chem. 2019, 165, 273–292. [Google Scholar] [CrossRef]
  80. Kazlauskas, R.; Murphy, P.T.; Quinn, R.J.; Wells, R.J. Heteronemin, a new scalarin type sesterterpene from the sponge Heteronema erecta. Tetrahedron Lett. 1976, 17, 2631–2634. [Google Scholar] [CrossRef]
  81. Alahdal, A.M.; Asfour, H.Z.; Ahmed, S.A.; Noor, A.O.; Al-Abd, A.M.; Elfaky, M.A.; Elhady, S.S. Anti-Helicobacter, antitubercular and cytotoxic activities of scalaranes from the red sea sponge Hyrtios erectus. Molecules 2018, 23, 978. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Marinedrugs 20 00373 g001 550
Figure 1. Isolation and molecular structures of the natural bengamides.
Figure 1. Isolation and molecular structures of the natural bengamides.
Marinedrugs 20 00373 g001
Marinedrugs 20 00373 g002 550
Figure 2. (a) Mode of the interaction of the bengamides at the active site of the methionine aminopeptidases. (b) Crystal structure of the human MetAP2-inhibitor complex for LAF-389. (Note: this figure is adapted with permissions from [19]. Copyright © 2003, the American Society for Biochemistry and Molecular Biology).
Figure 2. (a) Mode of the interaction of the bengamides at the active site of the methionine aminopeptidases. (b) Crystal structure of the human MetAP2-inhibitor complex for LAF-389. (Note: this figure is adapted with permissions from [19]. Copyright © 2003, the American Society for Biochemistry and Molecular Biology).
Marinedrugs 20 00373 g002
Marinedrugs 20 00373 g003 550
Figure 3. Representative natural bengamides and analogues and their cytotoxicities against MDA-MB-435 human breast cancer cells.
Figure 3. Representative natural bengamides and analogues and their cytotoxicities against MDA-MB-435 human breast cancer cells.
Marinedrugs 20 00373 g003
Marinedrugs 20 00373 sch001 550
Scheme 1. (a) Synthesis of bengamide analogues 29–33 and (b) benzocaprolactam derivatives 36–41 and their cytotoxicities against HCT116 cancer cell line.
Scheme 1. (a) Synthesis of bengamide analogues 29–33 and (b) benzocaprolactam derivatives 36–41 and their cytotoxicities against HCT116 cancer cell line.
Marinedrugs 20 00373 sch001
Marinedrugs 20 00373 g004 550
Figure 4. New bengamide analogues modified at the lactam fragment and their cytotoxicities against cancer cell lines.
Figure 4. New bengamide analogues modified at the lactam fragment and their cytotoxicities against cancer cell lines.
Marinedrugs 20 00373 g004
Marinedrugs 20 00373 sch002 550
Scheme 2. Synthesis of the caprolactam-modified bengamides 45–56 by MW irradiation.
Scheme 2. Synthesis of the caprolactam-modified bengamides 45–56 by MW irradiation.
Marinedrugs 20 00373 sch002
Marinedrugs 20 00373 g005 550
Figure 5. Molecular structures of the bengazoles.
Figure 5. Molecular structures of the bengazoles.
Marinedrugs 20 00373 g005
Marinedrugs 20 00373 g006 550
Figure 6. Molecular structures of the bengamide analogues 60–66.
Figure 6. Molecular structures of the bengamide analogues 60–66.
Marinedrugs 20 00373 g006
Marinedrugs 20 00373 sch003 550
Scheme 3. Synthesis of ring-opened bengamide analogues 68a–f and their biological activities against S. aureus (8325-4 strain).
Scheme 3. Synthesis of ring-opened bengamide analogues 68a–f and their biological activities against S. aureus (8325-4 strain).
Marinedrugs 20 00373 sch003
Marinedrugs 20 00373 g007 550
Figure 7. Bengamide analogues 69a–f, 70a–l and 71 and biological activities against S. aureus strain related to ClpP.
Figure 7. Bengamide analogues 69a–f, 70a–l and 71 and biological activities against S. aureus strain related to ClpP.
Marinedrugs 20 00373 g007
Marinedrugs 20 00373 g008 550
Figure 8. Molecular structures of the bengamide analogues 72a–g, 73a–m and 74–76.
Figure 8. Molecular structures of the bengamide analogues 72a–g, 73a–m and 74–76.
Marinedrugs 20 00373 g008
Table
Table 1. Natural sources and timeline of the isolation of the bengamides.
Table 1. Natural sources and timeline of the isolation of the bengamides.
YearNatural Source
(Collection Site)		Research GroupIsolated Compounds [Ref.]
1986Jaspis cf. coriacea
(Fiji Islands)		P. CrewsBengamides A and B [2]
1989Jaspis cf. coriacea
(Fiji Islands)		P. CrewsBengamides A–F [3]
1994Jaspis digonoxea
(South Africa)		Y. KashmanBengamides A and B [5]
1997Jaspis carteri
(New Caledonia)		M. V. D’AuriaBengamides A, B, G–J, K [6]
1999Jaspis splendens
(Serrurion Island)		M. R. BoydBengamides A, B, Y, Z [7]
1999Pachasctrissa sp.
(Musha Archipelago)		Y. LetourneuxBengamides A, B, L [8]
2001Jaspis cf. coriacea
(Fiji Islands)		P. CrewsBengamides M–R [4]
2008Dorypleres splendens
(Fiji Islands)		G. R. PettitBengamide A [9]
2011Stelleta sp.
(Bonaparte Archipelago)		C. A. MottiBengamides A, F, N and Y [10]
2012Myxococcus virescens
(German Collection of Microorganisms and Cell Cultures)		P. CrewsBengamides E, E’, F’ [12]
2015Myxococcus virescens
(Soil sample)		M. BrönstrupBengamides E, F, E’, F’ [13]
2019Calthropella sp.
(Indonesia)		R. T. SwasonoBengamide Q [11]
2022Jaspis splendens
(Mauritius)		D. W. GammonBengamides A, B, H, I, J, L, M, N, O, P, Q and R [16]
Table
Table 2. Antiproliferative activities of bengamide analogues 36, 39 and LAF389 (25) against a panel of 14 cancer cell lines (IC50 in nM).
Table 2. Antiproliferative activities of bengamide analogues 36, 39 and LAF389 (25) against a panel of 14 cancer cell lines (IC50 in nM).
Cancer Cell Line [a]Analogue 36Analogue 39 LAF389 (25)
A54993913
B16-F10334729
H46059429
HCT116445123
HCT15550451300
HT2912010027
MCF-7110 19
MDA-A148001100>10,000
MDA-MB-23111014022
PC327027020
CCRF-CEM35029065
HL6028037058
NHDF260140
PBL>5900 >7900
[a] A549: Non-small-cell lung cancer; B16-F10: Mouse skin cancer cells; H460: Human breast carcinoma; HCT116: colon cancer cells; HCT15: Human colorectal adenocarcinoma; HT29: Human colon adenocarcinoma; MCF-7: Epithelial cells from breast tissue with metastatic adenocarcinoma; MDA-A1: Human breast tumor cell line; MDA-MB-231: human breast carcinoma; PC3: Human prostate cancer cell line; CCRF-CEM: Human lymphoblastoid leukemia; HL60: human promyelocytic leukemia; NHDF: Normal human dermal fibroblast; PBL: Plasmablastic lymphoma.
Table
Table 3. Determination of IC50 (μM) of analogue 28 in tumor and non-tumor cell lines.
Table 3. Determination of IC50 (μM) of analogue 28 in tumor and non-tumor cell lines.
Cancer Cell Line [a] Marinedrugs 20 00373 i001Reference Compound [b]
CCD185.08 ± 0.397.35 ± 0.41
T840.07 ± 0.022.68 ± 0.16
SW4800.08 ± 0.006.35 ± 0.54
HCT152.44 ± 0.256.58 ± 0.35
HT290.66 ± 0.186.14 ± 0.94
MC386.51 ± 1.120.33 ± 0.01
MCF-70.13 ± 0.010.04 ± 0.01
[a] CCD18: Cell line with fibroblast morphology from normal colon tissue; T84: Transplantable human carcinoma cell line; SW480: Cells isolated from a male Dukes B colorectal cancer; HCT15: Human colorectal adenocarcinoma; HT29: Human colon adenocarcinoma; MC38: C57BL6 murine colon adenocarcinoma cells; MCF-7: Epithelial cells from breast tissue with metastatic adenocarcinoma. [b] The reference compounds were doxorubicin for MCF-7 and 5-fluoracil for the rest of the cell lines, corresponding to colon cell lines.
Table
Table 4. Determination of IC50 (μM) of analogues 51–56 in tumor cell lines.
Table 4. Determination of IC50 (μM) of analogues 51–56 in tumor cell lines.
AnalogueRTumor Cell Line
Sconfiguration, n = 1KB [a]LU1 [b]HepG-2 [c]MCF-7 [d]HL-60 [e]HeLa [f]
51aCyclohexyl8.212.711.820.1>50>50
52aPhenyl2.97.511.317.855.839.7
53aCinnamyl2.35.86.64.336.836.8
Rconfiguration, n = 1
51bCyclohexyl2.42.66.68.8>50>50
52bPhenyl4.42.712.020.429.019.7
53bCinnamyl1.72.32.415.121.516.1
Sconfiguration, n = 2
54aCyclohexyl11.817.1>50>50>50>50
55aPhenyl5.77.74.832.545.641.5
56aCinnamyl1.923.61.54.913.426.9
Rconfiguration, n = 2
54bCyclohexyl0.40.31.010.419.539.1
55bPhenyl1.01.11.98.610.616.2
56bCinnamyl1.125.10.42.78.99.5
[a] KB: Mouth epidermal carcinoma cells; [b] LU1: Human lung adenocarcinoma cells; [c] HepG-2: Human liver hepatocellular carcinoma cells; [d] MCF-7: Epithelial cells from breast tissue with metastatic adenocarcinoma; [e] HL60: Human promyelocytic leukemia cells; [f] HeLa: Human cervical carcinoma cells.
Table
Table 5. Biological activities of the bengamide analogues 60–66 against M. tuberculosis and human K562 cells.
Table 5. Biological activities of the bengamide analogues 60–66 against M. tuberculosis and human K562 cells.
AnalogueIC50 [μM] against MtMetAP1a [a]M. tuberculosis MIC [μM] [b]K562 [e]
IC50 [μM]
CoIIMnIIFeIIMABA [c]LORA [d]
606.0115.515%8%79.6
618.1126.748%12%96.5
6231111829%28%>333
634568670%0%>333
64881871100%0%>333
652149141220%>333
667.96.94.550.6107.437.8
[a] MtMetAP1a: MetAP of M. tuberculosis expressed in E. coli and purified as apo-enzyme. [b] Minimum inhibitory concentration or percent inhibition at 128 μM (IC50). [c] Microplate Alamar Blue assay against M. tuberculosis strain H37Rv (replicating phenotype). [d] Low-oxygen recovery assay against M. tuberculosis strain H37Rv-CA-lux AB (non-replicating persistent phenotype). [e] Human leukemia-derived cells.
Table
Table 6. Anti-MRSA activity of ring-opened bengamide analogues 72a–g, 73a–m and 74–76.
Table 6. Anti-MRSA activity of ring-opened bengamide analogues 72a–g, 73a–m and 74–76.
AnalogueMethicillin-Resistant Staphylococcus Aureus (MRSA) MIC [μg/mL] [a]
NewmanUSA300NRS-1NRS-70NRS-271NRS-108NRS-100
68a4.002.004.001.004.008.002.00
Van0.78–1.561.56–3.130.78–1.560.78–1.560.78–1.560.78–1.560.78–1.56
Tetra0.10–0.2012.5–25.025.00.39–0.780.20–0.390.10–0.200.10–0.20
72a12.5–25.012.5–25.06.25–12.50.78–1.5625.0–50.06.25–12.56.25–12.5
72b>50>50>50>50>50>50>50
72c25.0–50.050.050.050.050.050.050.0
72d6.25–12.512.5–25.06.25–12.56.25–12.512.5–256.25–12.56.25–12.5
72e3.13–6.251.56–3.133.13–6.251.56–3.136.25–12.50.78–1.560.78–1.56
72f12.5–25.025.0–50.025.0–50.05012.5–25.025.0–50.012.5–25.0
72g25.0–50.02525.0–50.0> 5025.0–50.05012.5–25.0
73a16.032.032.08.032.032.016.0
73b50505050505050
73c6.25–12.53.13–6.253.13–6.250.78–1.566.25–12.51.56–3.131.56–3.13
73d6.25–12.56.25–12.56.25–12.512.5–25.012.5–25.012.5–25.06.25–12.5
73e1.56–3.131.56–3.131.56–3.131.56–3.136.25–12.51.56–3.130.78–1.56
73f6.35–12.512.5–25.012.5–25.012.5–25.012.5–25.012.5–25.06.25–12.5
73g12.5–25.012.5–25.06.25–12.50.78–1.5625–506.25–12.56.25–12.5
73h1.56–3.130.78–1.561.56–3.131.56–3.133.13–6.253.13–6.250.78–1.56
73i0.39–0.780.78–1.560.39–0.780.78–1.560.78–1.560.78–1.56<0.39
73j0.078–0.1560.156–0.310.04–0.080.16–0.310.1–0.310.08–0.160.04–0.08
73k0.78–1.560.78–1.560.78–1.560.78–1.560.78–1.560.78–1.560.39–0.78
73l0.78–1.560.78–1.560.78–1.561.56–3.131.56–3.130.78–1.560.39–0.78
73m0.78–1.560.78–1.560.78–1.560.78–1.561.56–3.130.78–1.560.39–0.78
744.004.004.002.004.004.004.00
75>50>50>50>50>50>50>50
764.008.004.001.004.008.002.00
[a] The S. aureus strains employed were the following: (1) Strain NRS-1 (resistant to aminoglycosides and tetracycline); (2) strain NRS-70 (resistant to erythromycin); (3) strain NRS-100 (resistant to oxacillin and tetracycline); (4) strain NRS-108 (resistant to gentamicin); (5) NRS-271 (resistant to linezolid); (6) strain Newman (sensitive to methicillin) and (7) USA300 (CA-MRSA).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Porras-Alcalá, C.; Moya-Utrera, F.; García-Castro, M.; Sánchez-Ruiz, A.; López-Romero, J.M.; Pino-González, M.S.; Díaz-Morilla, A.; Kitamura, S.; Wolan, D.W.; Prados, J.; et al. The Development of the Bengamides as New Antibiotics against Drug-Resistant Bacteria. Mar. Drugs 2022, 20, 373. https://doi.org/10.3390/md20060373

AMA Style

Porras-Alcalá C, Moya-Utrera F, García-Castro M, Sánchez-Ruiz A, López-Romero JM, Pino-González MS, Díaz-Morilla A, Kitamura S, Wolan DW, Prados J, et al. The Development of the Bengamides as New Antibiotics against Drug-Resistant Bacteria. Marine Drugs. 2022; 20(6):373. https://doi.org/10.3390/md20060373

Chicago/Turabian Style

Porras-Alcalá, Cristina, Federico Moya-Utrera, Miguel García-Castro, Antonio Sánchez-Ruiz, Juan Manuel López-Romero, María Soledad Pino-González, Amelia Díaz-Morilla, Seiya Kitamura, Dennis W. Wolan, José Prados, and et al. 2022. "The Development of the Bengamides as New Antibiotics against Drug-Resistant Bacteria" Marine Drugs 20, no. 6: 373. https://doi.org/10.3390/md20060373

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop